Evaluation of Serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib
(0) Objective To evaluate SELDI as a potential technique for predicting response to gefitinib in NSCLC patients. Methods 36 serum samples of NSCLC patients (13 men and 23 women) who had received SELDI-TOF-MS (surfaceenhanced laser desorption/ionization time-of-flight mass spectrometry technique) inspection before treatment with gefitinib (250mg/day) were evaluated. Patients were to have measureable disease and received gefitinib for >1 month. Patients were categorized into 3 groups according to tumor response RECIST (Response Evaluation Criteria In Solid Tumors) to gefitinib: efficacy group (CR+PR), stable group (SD) and inefficacy group (PD). The mass spectrums were analyzed by Biomarker Wizard 3.1 Software and Protein Chip 3.2.0 Software. The work proceeded in 3 sequential stages. In the first stage, 9 patients were categorized into the 3 groups after treatment with gefitinib and the differences between their protein fingerprint groups analyzed. In the second stage, patients were divided into groups considered suitable or not suitable for gefitinib and the imprecise effect group according to the protein fingerprints identified in the first stage, so as to verify the coincidence between standardized fingerprints and clinical response. The third stage provided further confirmation of the relationship between fingerprint curve shape and its dynamic change and the response to gefitinib based on the findings from the first stage.
NSCLC SELDI-TOF-MS Gefitinib
PEIZi-qi HU Shou-xi ZHAO Yun PEI Yi JI Li-na WEI Shu-qing YAO Bi MA Xiao-jun YANG Yong-ming YUAN Li LI Qi JIPei-jun
Shanxi Medical University, 030001 Shanxi Tumor Hospital, 030013 Datong Fifth Municipal Peopes Hospital, 037008
国际会议
亚太地区国际肿瘤生物学和医学学术会议、全国肿瘤标志学术大会、第六届中国中青年肿瘤专家论坛
上海
英文
324-336
2011-10-13（万方平台首次上网日期，不代表论文的发表时间）